Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine kinase inhibitor

Biochem Biophys Res Commun. 1993 Jun 30;193(3):1152-8. doi: 10.1006/bbrc.1993.1746.

Abstract

Emodin (3-methyl-1,6,8-trihydroxyanthraquinone), a naturally occurring protein-tyrosine kinase inhibitor, selectively blocked the growth of v-ras-transformed human bronchial epithelial cells. Half-maximal inhibition of cell growth occurred at a concentration of 4 micrograms/ml. In contrast, emodin at a concentration of 100 micrograms/ml had little effect on the growth of normal human bronchial epithelial cells. Cell cycle analyses indicated that treatment with emodin arrested the v-ras-transformed cells in the G2/M phase of their cell cycle. Immunoblotting experiments using anti-phosphotyrosine antibodies indicated that ras-transformed cells, as compared to their normal counterparts, exhibited elevated levels of phosphotyrosine-containing proteins. Treatment with emodin resulted in a decrease in intracellular protein-tyrosine phosphorylation. These results suggest that compounds that inhibit the ras-dependent elevation in the level of tyrosine phosphorylated proteins may prove to be useful chemotherapeutic agents and may exhibit selective cytotoxicity against cancer cells with an activated ras oncogene.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Bronchi
  • Cell Cycle / drug effects
  • Cell Division
  • Cell Line
  • Cell Survival / drug effects
  • Cell Transformation, Neoplastic / drug effects*
  • Dose-Response Relationship, Drug
  • Doxorubicin / toxicity
  • Emodin / pharmacology*
  • Emodin / toxicity
  • Epithelium
  • Genes, ras*
  • Humans
  • Phosphotyrosine
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Tyrosine / analogs & derivatives
  • Tyrosine / analysis

Substances

  • Phosphotyrosine
  • Tyrosine
  • Doxorubicin
  • Protein-Tyrosine Kinases
  • Emodin